Fractyl Health specializes in developing innovative therapies that target the root cause of type 2 diabetes. The company's foundation is based on groundbreaking research and biological insights that highlight the crucial role of the intestine in metabolic control. Their unique therapies are designed to specifically address this aspect of metabolic disease. The lead program, Revita DMR, is a first-in-class procedural therapy currently in late-stage clinical trials for the treatment of type 2 diabetes. The team at Fractyl Health consists of passionate innovators who work at the intersection of biology and technology, striving to improve real-world outcomes for individuals with metabolic disease.
Legal Name
Fractyl Health, Inc.